JP2005523946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523946A5 JP2005523946A5 JP2004519536A JP2004519536A JP2005523946A5 JP 2005523946 A5 JP2005523946 A5 JP 2005523946A5 JP 2004519536 A JP2004519536 A JP 2004519536A JP 2004519536 A JP2004519536 A JP 2004519536A JP 2005523946 A5 JP2005523946 A5 JP 2005523946A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- binding site
- tnfα
- human
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims 54
- 102000036639 antigens Human genes 0.000 claims 54
- 108091007433 antigens Proteins 0.000 claims 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 201000010099 disease Diseases 0.000 claims 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 30
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 19
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 19
- 102000057041 human TNF Human genes 0.000 claims 19
- 238000006467 substitution reaction Methods 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 14
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 13
- 229960004194 lidocaine Drugs 0.000 claims 13
- 239000000126 substance Substances 0.000 claims 13
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 12
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 12
- 235000001014 amino acid Nutrition 0.000 claims 12
- 229910052791 calcium Inorganic materials 0.000 claims 12
- 239000011575 calcium Substances 0.000 claims 12
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 12
- 229960000590 celecoxib Drugs 0.000 claims 12
- 229960000304 folic acid Drugs 0.000 claims 12
- 235000019152 folic acid Nutrition 0.000 claims 12
- 239000011724 folic acid Substances 0.000 claims 12
- 238000004519 manufacturing process Methods 0.000 claims 12
- -1 multivitamins Chemical compound 0.000 claims 12
- 229960005489 paracetamol Drugs 0.000 claims 12
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 12
- 229960000371 rofecoxib Drugs 0.000 claims 12
- 229960004380 tramadol Drugs 0.000 claims 12
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 12
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 12
- 229960005294 triamcinolone Drugs 0.000 claims 12
- 241000712461 unidentified influenza virus Species 0.000 claims 12
- 229940031348 multivalent vaccine Drugs 0.000 claims 11
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 11
- 208000023275 Autoimmune disease Diseases 0.000 claims 10
- 230000001627 detrimental effect Effects 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 10
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 9
- 230000003013 cytotoxicity Effects 0.000 claims 9
- 231100000135 cytotoxicity Toxicity 0.000 claims 9
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 9
- 235000004279 alanine Nutrition 0.000 claims 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 238000003556 assay Methods 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 102000004889 Interleukin-6 Human genes 0.000 claims 6
- 108090001005 Interleukin-6 Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003929 folic acid group Chemical group 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010037660 Pyrexia Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000010494 dissociation reaction Methods 0.000 claims 4
- 230000005593 dissociations Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 229940100601 interleukin-6 Drugs 0.000 claims 4
- 201000004792 malaria Diseases 0.000 claims 4
- 208000023504 respiratory system disease Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000003322 Coinfection Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000019155 Radiation injury Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims 2
- 201000009904 bacterial meningitis Diseases 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 208000019664 bone resorption disease Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 2
- 229940076085 gold Drugs 0.000 claims 2
- 239000010931 gold Substances 0.000 claims 2
- 229910052737 gold Inorganic materials 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000011379 keloid formation Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 230000009772 tissue formation Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/133,715 US20030206898A1 (en) | 2002-04-26 | 2002-04-26 | Use of anti-TNFalpha antibodies and another drug |
| PCT/US2003/012976 WO2004004633A2 (en) | 2002-04-26 | 2003-04-24 | Use of tnfalpha antibodies and another drug |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010118647A Division JP2010248199A (ja) | 2002-04-26 | 2010-05-24 | ＴＮＦα抗体および他の薬剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523946A JP2005523946A (ja) | 2005-08-11 |
| JP2005523946A5 true JP2005523946A5 (cg-RX-API-DMAC7.html) | 2006-12-07 |
Family
ID=29268783
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519536A Withdrawn JP2005523946A (ja) | 2002-04-26 | 2003-04-24 | ＴＮＦα抗体および他の薬剤の使用 |
| JP2010118647A Pending JP2010248199A (ja) | 2002-04-26 | 2010-05-24 | ＴＮＦα抗体および他の薬剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010118647A Pending JP2010248199A (ja) | 2002-04-26 | 2010-05-24 | ＴＮＦα抗体および他の薬剤の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20030206898A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1501545A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2005523946A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100106631A (cg-RX-API-DMAC7.html) |
| CN (3) | CN101229371A (cg-RX-API-DMAC7.html) |
| AR (2) | AR039656A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2003278692B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0306444A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2385777A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL164759A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04010498A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ560793A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20040474A1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL373333A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TWI353851B (cg-RX-API-DMAC7.html) |
| UY (1) | UY27780A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004004633A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200408509B (cg-RX-API-DMAC7.html) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| US20040136991A1 (en) * | 2002-07-19 | 2004-07-15 | Abbott Biotechnology Ltd. | Treatment of anemia using TNFalpha inhibitors |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| JP5117189B2 (ja) * | 2004-08-27 | 2013-01-09 | サイクラセル リミテッド | プリン及びピリミジンｃｄｋ阻害剤、並びに自己免疫疾患の治療のためのそれらの使用 |
| US20060083741A1 (en) * | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| EP1885397A4 (en) | 2005-05-16 | 2010-01-20 | Abbott Biotech Ltd | USE OF A TNF HEMMER FOR THE TREATMENT OF EROSIVE POLYARTHRITIS |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| DK1948235T3 (da) | 2005-11-01 | 2013-11-25 | Abbvie Biotechnology Ltd | Fremgangsmåder til bestemmelse af effektiviteten af adalimumab hos patienter med Bechterews sygdom med CTX-II og MMP3 som biomarkører |
| EP2738178A1 (en) | 2006-04-05 | 2014-06-04 | AbbVie Biotechnology Ltd | Antibody purification |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) * | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| TWI527603B (zh) | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| NZ613356A (en) | 2006-10-27 | 2015-02-27 | Abbvie Biotechnology Ltd | Crystalline anti-htnfalpha antibodies |
| US8092998B2 (en) * | 2007-05-31 | 2012-01-10 | Abbott Laboratories | Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders |
| EP2152318A4 (en) * | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
| WO2009011782A2 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| TW200938221A (en) | 2007-11-30 | 2009-09-16 | Abbott Lab | Protein formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| CA2708221C (en) * | 2007-12-06 | 2017-07-25 | Wayne A. Marasco | Antibodies against influenza virus and methods of use thereof |
| EP2238446A4 (en) * | 2008-01-03 | 2011-07-20 | Abbott Biotech Ltd | PREDICTING THE LONG-TERM EFFECT OF A CONNECTION IN THE TREATMENT OF PSORIASIS |
| NZ601913A (en) | 2008-01-15 | 2014-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| BRPI0915448A2 (pt) | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
| US20100016265A1 (en) * | 2008-07-16 | 2010-01-21 | Qaiser Yusuf | Anti-inflammatory composition and method for preparation |
| CA2758964A1 (en) | 2009-04-16 | 2010-10-21 | Abbott Biotherapeutics Corp. | Anti-tnf-.alpha. antibodies and their uses |
| BRPI1012162A2 (pt) | 2009-04-29 | 2016-01-12 | Abbott Biotech Ltd | dispositivo de injeção automática |
| JP2013503607A (ja) * | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
| MX2012004415A (es) * | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011075524A1 (en) | 2009-12-15 | 2011-06-23 | Abbott Biotechnology Ltd | Improved firing button for automatic injection device |
| RU2012147249A (ru) * | 2010-04-07 | 2014-05-20 | Эббви Инк. | TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ |
| CN103079594B (zh) | 2010-06-03 | 2016-04-13 | 艾伯维生物技术有限公司 | 用于治疗化脓性汗腺炎(hs)的用途和组合物 |
| JP2013537415A (ja) | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| TWI606840B (zh) | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物 |
| CA2825316C (en) | 2011-01-24 | 2020-05-05 | Abbvie Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
| CN102675460B (zh) * | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
| JP2014508715A (ja) * | 2011-03-07 | 2014-04-10 | 国立大学法人徳島大学 | 筋萎縮性側索硬化症の治療方法 |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| WO2014035475A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| CN104768576A (zh) | 2012-09-07 | 2015-07-08 | 科荣生生物科学公司 | 稳定的阿达木单抗水性制剂 |
| RS56093B1 (sr) | 2012-09-19 | 2017-10-31 | Abbvie Biotherapeutics Inc | Postupci za identifikovanje antitela sa smanjenom imunogenošću |
| KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2769736A1 (en) | 2013-02-22 | 2014-08-27 | Bill, Anja | Pharmaceutical composition for the treatment of burnout syndrome |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| EP3447075B1 (en) * | 2015-05-15 | 2023-08-09 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| CA3019751A1 (en) * | 2016-04-04 | 2017-10-12 | Gu Ventures Ab | Methods and compositions for the treatment of intervertebral disc herniation |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| CA3040899A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| CN106918633B (zh) * | 2017-04-24 | 2019-06-25 | 中国科学院苏州生物医学工程技术研究所 | 基于适体和金磁纳米颗粒的细胞因子TNF-α的检测方法 |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| CN111755070A (zh) * | 2019-03-29 | 2020-10-09 | 中山大学 | 一种基于级联判决系统的CircRNA功能预测方法 |
| TW202228775A (zh) | 2020-10-14 | 2022-08-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物及方法 |
| CN116635024A (zh) * | 2020-10-14 | 2023-08-22 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| US20230084477A1 (en) | 2021-08-10 | 2023-03-16 | Viridian Therapeutics, Inc. | Compositions, doses, and methods for treatment of thyroid eye disease |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| IL73883A (en) | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| EP0230574A3 (en) | 1986-01-31 | 1989-03-22 | Yale University | Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| EP0374510B1 (en) | 1988-12-19 | 1997-01-15 | American Cyanamid Company | Products for the treatment of endotoxic shock in a mammal |
| GB8921123D0 (en) | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| DE4037604A1 (de) | 1990-04-25 | 1991-10-31 | Bayer Ag | Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH06500323A (ja) | 1990-08-27 | 1994-01-13 | ペプチド テクノロジィ リミテッド | ウイルス性感染の治療方法 |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| SG89295A1 (en) | 1991-03-15 | 2002-06-18 | Amgen Inc | Pegylation of polypeptides |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| EP1097945B1 (en) | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| ES2123515T3 (es) | 1991-03-29 | 1999-01-16 | Immunex Corp | Antagonistas de citoquinas a base de proteinas virales aisladas. |
| US5658727A (en) | 1991-04-10 | 1997-08-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| WO1993011793A1 (en) * | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
| AU3924993A (en) | 1992-04-02 | 1993-11-08 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| DE69321909T2 (de) | 1992-08-28 | 1999-04-01 | Bayer Corp., Pittsburgh, Pa. | Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| AU682156B2 (en) | 1992-10-15 | 1997-09-25 | Dana-Farber Cancer Institute, Inc. | Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function |
| EP0614984B2 (en) | 1993-03-05 | 2010-11-03 | Bayer HealthCare LLC | Anti-TNF alpha human monoclonal antibodies |
| DE4307508A1 (de) | 1993-03-10 | 1994-09-15 | Knoll Ag | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche) |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| US5574022A (en) | 1994-04-14 | 1996-11-12 | The Center For Innovative Technology | Method of attenuating physical damage to the spinal cord |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1997029131A1 (en) * | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| WO1999036077A1 (en) * | 1998-01-19 | 1999-07-22 | Dcv, Inc. | Composition and method for treatment and prevention of arthritis and/or autoimmune diseases |
| AU2372400A (en) * | 1999-01-19 | 2000-08-07 | Dcv, Inc. | Egg anti-inflammatory composition and method of treating and preventing inflammation |
| NZ515711A (en) * | 1999-06-24 | 2004-01-30 | Pharmacia Corp | Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation |
| AU3082401A (en) * | 1999-11-24 | 2001-06-04 | Centocor Inc. | Therapy of psoriasis |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| CA2385745C (en) * | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
-
2002
- 2002-04-26 US US10/133,715 patent/US20030206898A1/en not_active Abandoned
- 2002-05-10 CA CA002385777A patent/CA2385777A1/en active Pending
-
2003
- 2003-04-24 BR BR0306444-1A patent/BR0306444A/pt not_active IP Right Cessation
- 2003-04-24 MX MXPA04010498A patent/MXPA04010498A/es unknown
- 2003-04-24 WO PCT/US2003/012976 patent/WO2004004633A2/en not_active Ceased
- 2003-04-24 AU AU2003278692A patent/AU2003278692B2/en not_active Ceased
- 2003-04-24 EP EP03762970A patent/EP1501545A4/en not_active Withdrawn
- 2003-04-24 EP EP10182508A patent/EP2347766A1/en not_active Withdrawn
- 2003-04-24 KR KR1020107021349A patent/KR20100106631A/ko not_active Ceased
- 2003-04-24 EP EP10155524A patent/EP2196218A3/en not_active Withdrawn
- 2003-04-24 CN CNA2007101692298A patent/CN101229371A/zh active Pending
- 2003-04-24 CN CN2010101480474A patent/CN101890163A/zh active Pending
- 2003-04-24 CN CNA038094371A patent/CN1649624A/zh active Pending
- 2003-04-24 AR ARP030101417A patent/AR039656A1/es not_active Application Discontinuation
- 2003-04-24 NZ NZ560793A patent/NZ560793A/en not_active IP Right Cessation
- 2003-04-24 PL PL03373333A patent/PL373333A1/xx not_active Application Discontinuation
- 2003-04-24 JP JP2004519536A patent/JP2005523946A/ja not_active Withdrawn
- 2003-04-25 UY UY27780A patent/UY27780A1/es not_active Application Discontinuation
- 2003-04-25 PE PE2003000417A patent/PE20040474A1/es not_active Application Discontinuation
- 2003-04-25 TW TW092109743A patent/TWI353851B/zh not_active IP Right Cessation
- 2003-04-25 TW TW100124823A patent/TW201138826A/zh unknown
-
2004
- 2004-10-20 ZA ZA200408509A patent/ZA200408509B/en unknown
- 2004-10-21 IL IL16475904A patent/IL164759A0/xx unknown
-
2009
- 2009-03-02 AU AU2009200817A patent/AU2009200817A1/en not_active Abandoned
-
2010
- 2010-05-24 JP JP2010118647A patent/JP2010248199A/ja active Pending
- 2010-07-14 AR ARP100102558A patent/AR077473A2/es not_active Application Discontinuation
- 2010-10-31 IL IL209010A patent/IL209010A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523946A5 (cg-RX-API-DMAC7.html) | ||
| JP7286595B2 (ja) | 抗体製剤 | |
| CN100556450C (zh) | Il-18抑制剂在治疗或预防脓毒症中的应用 | |
| FI101937B (fi) | Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmi sen cachectiinin kanssa | |
| JP2020505381A5 (cg-RX-API-DMAC7.html) | ||
| JP2004501101A5 (cg-RX-API-DMAC7.html) | ||
| CA2568352A1 (en) | Methods of using il-1 antagonists to treat autoinflammatory disease | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| RU2003120859A (ru) | Способ ингибирования активности человеческого tnfa (варианты), применение выделенного антитела человека или его антиген-связывающего фрагмента в качестве компонента для производства лекарственного средства (варианты) и выделенное человеческое антитело или его антиген-связывающий фрагмент | |
| JP2010533181A5 (cg-RX-API-DMAC7.html) | ||
| JP6469012B2 (ja) | インターロイキン−６に対する抗体およびその使用 | |
| JP2006506465A5 (cg-RX-API-DMAC7.html) | ||
| AU2012312225B2 (en) | Cachexia treatment | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| US9669077B2 (en) | Method for treating chronic colitis and systemic sclerosis and for eliciting a protective immune reaction against human IL-6 | |
| RU2010126598A (ru) | Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в | |
| US20130195877A1 (en) | Treatment of cachexia by targeting interleukin-1 beta | |
| JPWO2006046661A1 (ja) | インターロイキン−６阻害剤 | |
| JP2003531822A (ja) | 自己免疫疾患を治療するためのｔｈ−１免疫反応誘導サイトカインの拮抗薬 | |
| EP2138513B1 (en) | Pharmaceutical compositions of antibodies for diseases caused by viruses | |
| JP2005529152A5 (cg-RX-API-DMAC7.html) | ||
| JP2020531480A5 (cg-RX-API-DMAC7.html) | ||
| US20240009275A1 (en) | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment | |
| CA3176673A1 (en) | Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease | |
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 |